Literature DB >> 6706424

Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors.

A W Richter, E Akerblom.   

Abstract

Antibodies to polyethylene glycol (PEG) were analyzed in patients with various allergies and in healthy blood donors employing passive hemagglutination. In untreated allergic patients and in healthy blood donors, naturally occurring anti-PEG antibody titers between 32 and 512 were seen in 3.3 and 0.2%, respectively. During hyposensitization with monomethoxy polyethylene glycol modified ragweed extract and honey bee venom, respectively, the patients showed an anti-PEG antibody response. Titers of 32-512 were found in 50% of the patients directly after the first treatment course. After 2 years of treatment the percentage of patients with such titers declined to 28.5%. Mercaptoethanol treatment of sera indicated that the anti-PEG antibodies predominantly were of the IgM isotype. The weak IgM response found in treated patients is considered to be of no clinical significance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6706424     DOI: 10.1159/000233512

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  51 in total

Review 1.  Protein-polymer conjugation-moving beyond PEGylation.

Authors:  Yizhi Qi; Ashutosh Chilkoti
Journal:  Curr Opin Chem Biol       Date:  2015-09-07       Impact factor: 8.822

Review 2.  Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications.

Authors:  Neetu M Gulati; Phoebe L Stewart; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2018-05-15       Impact factor: 4.939

3.  POxylation as an alternative stealth coating for biomedical applications.

Authors:  Herdis Bludau; Anna E Czapar; Andrzej S Pitek; Sourabh Shukla; Rainer Jordan; Nicole F Steinmetz
Journal:  Eur Polym J       Date:  2016-11-05       Impact factor: 4.598

Review 4.  Watching the gorilla and questioning delivery dogma.

Authors:  Thomas J Anchordoquy; Dmitri Simberg
Journal:  J Control Release       Date:  2017-07-14       Impact factor: 9.776

5.  The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

Authors:  Christian Lubich; Peter Allacher; Maurus de la Rosa; Alexander Bauer; Thomas Prenninger; Frank Michael Horling; Jürgen Siekmann; Johannes Oldenburg; Friedrich Scheiflinger; Birgit Maria Reipert
Journal:  Pharm Res       Date:  2016-06-07       Impact factor: 4.200

Review 6.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

7.  Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.

Authors:  C A Fernandez; E Stewart; J C Panetta; M R Wilkinson; A R Morrison; F D Finkelman; J T Sandlund; C H Pui; S Jeha; M V Relling; P K Campbell
Journal:  Cancer Chemother Pharmacol       Date:  2014-04-27       Impact factor: 3.333

8.  Serum albumin 'camouflage' of plant virus based nanoparticles prevents their antibody recognition and enhances pharmacokinetics.

Authors:  Andrzej S Pitek; Slater A Jameson; Frank A Veliz; Sourabh Shukla; Nicole F Steinmetz
Journal:  Biomaterials       Date:  2016-02-23       Impact factor: 12.479

9.  Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.

Authors:  Li Xue; Adrienne Clements-Egan; Lakshmi Amaravadi; Mary Birchler; Boris Gorovits; Meina Liang; Heather Myler; Shobha Purushothama; Marta Starcevic Manning; Crystal Sung
Journal:  AAPS J       Date:  2017-11-06       Impact factor: 4.009

Review 10.  The immunogenicity of polyethylene glycol: facts and fiction.

Authors:  Huub Schellekens; Wim E Hennink; Vera Brinks
Journal:  Pharm Res       Date:  2013-05-15       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.